135 related articles for article (PubMed ID: 38229370)
1. Raynaud's phenomenon: no net effects of vasodilators in a network analysis.
Jaeger VK; Walker UA
Lancet Rheumatol; 2019 Dec; 1(4):e200-e202. PubMed ID: 38229370
[No Abstract] [Full Text] [Related]
2. Pharmacotherapy of Raynaud's phenomenon.
Belch JJ; Ho M
Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon.
Khan F; Coffman JD
Circulation; 1994 Mar; 89(3):1183-8. PubMed ID: 8124805
[TBL] [Abstract][Full Text] [Related]
4. Raynaud's phenomenon.
Wigley FM; Flavahan NA
Rheum Dis Clin North Am; 1996 Nov; 22(4):765-81. PubMed ID: 8923595
[TBL] [Abstract][Full Text] [Related]
5. Office evaluation and treatment of Raynaud's phenomenon.
Bolster MB; Maricq HR; Leff RL
Cleve Clin J Med; 1995; 62(1):51-61. PubMed ID: 7859402
[TBL] [Abstract][Full Text] [Related]
6. Peripheral vasodilators and the management of peripheral vascular disease and Raynaud's syndrome in general practice.
Connolly JP; McGavock H; Wilson-Davis K
Pharmacoepidemiol Drug Saf; 1998 May; 7(3):189-96. PubMed ID: 15073997
[TBL] [Abstract][Full Text] [Related]
7. Raynaud's phenomenon. An update.
Coffman JD
Hypertension; 1991 May; 17(5):593-602. PubMed ID: 2022404
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials.
Khouri C; Lepelley M; Bailly S; Blaise S; Herrick AL; Matucci-Cerinic M; Allanore Y; Trinquart L; Cracowski JL; Roustit M
Lancet Rheumatol; 2019 Dec; 1(4):e237-e246. PubMed ID: 38229380
[TBL] [Abstract][Full Text] [Related]
9. Raynaud's phenomenon.
Lally EV
Curr Opin Rheumatol; 1992 Dec; 4(6):825-36. PubMed ID: 1457277
[TBL] [Abstract][Full Text] [Related]
10. Raynaud's phenomenon.
Herrick AL
J Scleroderma Relat Disord; 2019 Jun; 4(2):89-101. PubMed ID: 35382391
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Raynaud's phenomenon in young Greek males.
Tzilalis V; Panagiotopoulos N; Papatheodorou G; Rallis E; Kassimos D
Clin Rheumatol; 2011 Jan; 30(1):57-9. PubMed ID: 21120563
[TBL] [Abstract][Full Text] [Related]
12. Raynaud's Phenomenon with Focus on Systemic Sclerosis.
Maciejewska M; Sikora M; Maciejewski C; Alda-Malicka R; Czuwara J; Rudnicka L
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566614
[TBL] [Abstract][Full Text] [Related]
13. Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.
Rembold CM; Ayers CR
Mol Cell Biochem; 2003 Feb; 244(1-2):139-41. PubMed ID: 12701823
[TBL] [Abstract][Full Text] [Related]
14. Chromosome aberrations in Raynaud's phenomenon.
Porciello G; Scarpato R; Storino F; Migliore L; Ferri C; Cagetti F; Morozzi G; Bellisai F; Marcolongo R; Galeazzi M
Eur J Dermatol; 2004; 14(5):327-31. PubMed ID: 15358572
[TBL] [Abstract][Full Text] [Related]
15. [Prevalence of Raynaud's phenomenon in individuals not using vibrating tools].
Iwata H; Makimo S; Miyashita K
Sangyo Igaku; 1987 Nov; 29(6):500-3. PubMed ID: 3448316
[TBL] [Abstract][Full Text] [Related]
16. The origin of Raynaud's phenomenon.
Nielubowicz J; Zajaç S; Szamowska R; Adamski M
J Cardiovasc Surg (Torino); 1978; 19(6):607-14. PubMed ID: 739033
[TBL] [Abstract][Full Text] [Related]
17. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis.
O'Reilly D; Taylor L; el-Hadidy K; Jayson MI
Ann Rheum Dis; 1992 Nov; 51(11):1193-6. PubMed ID: 1466594
[TBL] [Abstract][Full Text] [Related]
18. Calcium channel blockers for primary and secondary Raynaud's phenomenon.
Rirash F; Tingey PC; Harding SE; Maxwell LJ; Tanjong Ghogomu E; Wells GA; Tugwell P; Pope J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD000467. PubMed ID: 29237099
[TBL] [Abstract][Full Text] [Related]
19. Calcium channel blockers for primary Raynaud's phenomenon.
Ennis H; Anderson ME; Wilkinson J; Herrick AL
Cochrane Database Syst Rev; 2014 Jan; (1):CD002069. PubMed ID: 24482037
[TBL] [Abstract][Full Text] [Related]
20. Arm heating to relieve Raynaud's phenomenon in systemic sclerosis: A single-arm multicentre prospective clinical trial.
Watanabe A; Shima Y; Takahashi H; Akiyama Y; Kodera M; Jinnin M; Azuma N; Ishii K; Kumanogoh A
Mod Rheumatol; 2023 Aug; 33(5):968-974. PubMed ID: 36124934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
